Neumora Therapeutics, Inc. (NASDAQ:NMRA) will release earnings for the fourth quarter, before the opening bell on Monday, March 30.

Analysts expect the Watertown, Massachusetts-based company to report a quarterly loss of 33 cents per share, versus a year-ago loss of 37 cents per share, according to Benzinga Pro.

Neumora Therapeutics, on Jan. 5, shared results from its Phase 1b signal-seeking study of NMRA-511 for Alzheimer's disease (AD) agitation. NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.

Shares of Neumora Therapeutics dipped 6.4% to trade at $2.33 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • William Blair analyst Myles Minter upgraded the stock from Market Perform to Outperform on Feb. 17, 2026. This analyst has an accuracy rate of 58%.
  • Leerink Partners analyst Marc Goodman initiated coverage on the stock with an Outperform rating on Jan. 12, 2026. This analyst has an accuracy rate of 71%.
  • RBC Capital analyst Brian Abrahams upgraded the stock from Sector Perform to Outperform and raised the price target from $4 to $7 on Dec. 1, 2025. This analyst has an accuracy rate of 54%.
  • Needham analyst Ami Fadia maintained a Buy rating and raised the price target from $6 to $8 on Oct. 28, 2025. This analyst has an accuracy rate of 73%.
  • Guggenheim analyst Yatin Suneja upgraded the stock from Neutral to Buy with a price target of $14 on Oct. 27, 2025. This analyst has an accuracy rate of 74%

Considering buying NMRA stock? Here’s what analysts think:

Photo via Shutterstock